Introduction: From Step Counters to Clinical Instruments

A decade ago, a wearable medical device meant a bulky Holter monitor taped to a patient's chest for 24 hours or an insulin pump the size of a pager. Today, the same clinical functions, continuous glucose tracking, single-lead electrocardiography, blood-oxygen measurement, arrhythmia detection, even hypertension screening are running quietly on devices worn on the wrist, forearm, or finger, often the same devices people already use to count steps. The wearable medical devices market sits at the intersection of consumer electronics, diagnostics, and connected care: it comprises sensor-equipped devices, from smartwatches and biosensor patches to smart rings and wearable defibrillators, that continuously or intermittently capture physiological data and, increasingly, translate that data into clinically actionable information.

The significance of this shift is best understood against the scale of the chronic-disease burden it is trying to address. The World Health Organization reports that cardiovascular diseases remain the leading cause of death worldwide, responsible for an estimated 19.8 million deaths in 2022, or roughly 32 percent of all global deaths, with the large majority attributable to heart attack and stroke. The International Diabetes Federation's 2025 Diabetes Atlas found that 589 million adults were living with diabetes globally, with 252 million of them undiagnosed, and projected the total to reach 853 million by 2050. Diabetes-related health expenditure surpassed one trillion US dollars in 2024. These are not abstract statistics, they are the demand signal behind every regulatory clearance, product launch, and partnership described in this article. A device that can flag an irregular heart rhythm before a stroke, or extend glucose-sensor wear time so a patient checks their phone less often, is competing directly against these mortality and cost curves.

What is changing most quickly is not the underlying sensor physics, optical heart-rate sensing, electrochemical glucose sensing, and single-lead ECG have existed for years but the software, artificial intelligence, and regulatory pathways layered on top of them. Devices that once served general wellness purposes are now clearing the US Food and Drug Administration's 510(k) and De Novo pathways as genuine medical devices, and clinical-grade monitors once confined to hospitals are shrinking into patches and rings suitable for the home. Understanding this market today means understanding three simultaneous developments, the convergence of consumer and clinical devices, the embedding of AI-driven diagnostics into everyday hardware, and the migration of monitoring and even treatment out of the hospital and into daily life.

The Great Convergence: Consumer Wearables Earn Clinical Credentials

The clearest trend shaping the market is the erosion of the line between a wellness gadget and a regulated medical device. Apple's Series 11 and Ultra 3 watches, launched in September 2025, introduced FDA-cleared hypertension notifications that use the optical heart sensor to analyze how blood vessels respond to each heartbeat over rolling 30-day windows, flagging patterns consistent with chronic high blood pressure. According to Apple's own newsroom disclosures, the underlying machine-learning model was trained on data from more than 100,000 participants across multiple studies and validated in a clinical study of over 2,000 people; the company expects the feature to notify more than one million users with previously undiagnosed hypertension within its first year. Because hypertension is, in the WHO's words, a condition that frequently produces no symptoms and is easily missed in a single clinical measurement, a passive, always-on detector represents a meaningfully different screening model than the periodic blood-pressure cuff reading that has defined primary care for decades.

Samsung reached a parallel milestone earlier, becoming the first company to win FDA De Novo authorization, in February 2024, for a smartwatch-based sleep apnea detection feature. The Samsung Health Monitor app, paired with a compatible Galaxy Watch, screens adults aged 22 and older who have not previously been diagnosed with the condition, looking for signs of moderate to severe obstructive sleep apnea over a two-night monitoring period. Samsung has continued to build on this cardiovascular and sleep-monitoring foundation, and in 2025 the company expanded further into clinical software through its acquisition of the digital-health platform Xealth, aimed at feeding wearable-generated wellness data directly into clinician workflows rather than leaving it siloed in a consumer app.

Fitness-focused wearable maker WHOOP illustrates the same convergence from the opposite direction, a device built for athletic recovery tracking that has steadily added regulated clinical features. In 2025, WHOOP unveiled its WHOOP 5.0 and WHOOP MG devices with an FDA-cleared, on-demand single-lead ECG feature, branded Heart Screener, capable of detecting atrial fibrillation, alongside irregular-rhythm notifications and blood-pressure insights. The FDA's own 510(k) database record for the ECG feature (K243236) confirms clearance on April 2025, built on the previously cleared B-Secur HeartKey software library, and classifies the feature for over-the-counter cardiovascular use. Notably, WHOOP's parallel blood-pressure insights feature drew an FDA warning letter later in 2025 over its unauthorized medical claims before the matter was resolved, a reminder that the boundary between a general-wellness feature and a regulated diagnostic claim is being actively tested and enforced, not simply assumed.

AI and Software as a Medical Device: The Diagnostic Engine on the Wrist

Nearly every clearance described in this article is, at its core, a software clearance. The hardware, an optical sensor, an electrode, an accelerometer is often incremental, the differentiator is the machine-learning model interpreting the resulting waveform. This is why the FDA increasingly evaluates these products under its Software as a Medical Device and AI/ML-enabled device frameworks rather than treating them purely as hardware innovations. Between October 2024 and May 2025 alone, the agency cleared a wave of sensor-based digital health technologies spanning continuous glucose monitoring, wearable ECG, and ambulatory blood-pressure sensing, reflecting a steady cadence of AI-enabled wearable clearances rather than a single breakthrough event.

This software-centric shift changes how companies compete. A firm's value increasingly rests on its accumulated training data and its ability to retrain and re-validate algorithms as clearance categories evolve, not solely on manufacturing precision sensors. It also changes the pace of iteration, because many of these products are cleared as software running on established hardware platforms, companies can push clinically meaningful updates, a new hypertension algorithm, an expanded arrhythmia classifier, through app updates rather than new hardware cycles, provided each material change clears its own regulatory review. The result is a market where the meaningful competitive battleground has moved from the sensor to the model, and where partnerships between hardware manufacturers and specialist diagnostic software developers, such as WHOOP's integration of B-Secur's HeartKey ECG library, are becoming a standard route to market rather than an exception.

Explore the Wearable Medical Devices Market - Get Your Free Sample Report Today:
https://www.igtps.com/report/wearable-medical-devices-market

Continuous Glucose Monitoring: The Metabolic-Health Frontier

No category better illustrates the pace of innovation than continuous glucose monitoring. On April 2025, Dexcom announced FDA clearance of its Dexcom G7 15 Day system for adults 18 and older with diabetes, extending sensor wear from ten to 15.5 days, including a 12-hour grace period,  while improving overall accuracy to a mean absolute relative difference of 8.0 percent, according to the company's investor announcement. Dexcom describes the G7 15 Day as the longest-wearing continuous glucose monitor cleared in the United States and notes it is working with insulin-pump partners to make the sensor compatible with automated insulin-delivery systems ahead of a planned second-half-2025 commercial launch. Longer wear time directly reduces the number of insertions a patient must perform each month, which matters clinically because sensor-change friction is a well-documented driver of therapy discontinuation.

Glucose monitoring is also moving beyond the traditionally diagnosed diabetes population and into general metabolic wellness, and CGM makers are pursuing distribution partnerships with consumer wearable brands to get there. Dexcom's partnership with sleep- and recovery-focused ring maker Oura, first announced in late 2024, is aimed at combining continuous glucose data with activity, sleep, and recovery metrics inside a single consumer experience, an approach that treats glucose variability as a mainstream wellness signal rather than a diabetes-only metric. This mirrors a broader industry pattern in which glucose, cardiac, and sleep data streams that were once collected by separate single-purpose medical devices are being fused into unified, AI-interpreted health dashboards accessible to both patients and, increasingly, their clinicians through electronic health record integrations.

Cardiac Monitoring Goes Mainstream: ECG, AFib, and Hypertension Detection

Cardiovascular applications dominate the wearable medical device pipeline for good reason, the WHO's data on CVD as the single largest cause of death globally makes early detection one of the highest-leverage interventions available to any device maker. Beyond the Apple and WHOOP clearances already discussed, the FDA authorized Masimo's W1 watch under a 510(k) clearance in May 2025, extending pulse-oximetry-grade physiological monitoring, a technology Masimo states is used on more than 200 million patients annually in hospital settings into a consumer wearable form factor. Element Science's Jewel Patch Wearable Cardioverter Defibrillator, cleared in May 2025, pushes the category further still, moving from passive detection toward active, wearable intervention for patients at temporary risk of sudden cardiac arrest, a segment historically served only by bulky vest-style defibrillators.

The strategic logic connecting these clearances is consistent, cardiac events are frequently asymptomatic until they are catastrophic, and a continuously worn sensor converts an episodic, clinic-based screening model into an always-on one. For clinicians and health systems, this shifts part of the diagnostic burden earlier and outward into daily life, which can reduce costly emergency interventions downstream, provided the alerts generated are accurate enough to avoid overwhelming primary-care follow-up capacity with false positives.

From Hospital Bed to Home: Remote Patient Monitoring and Ambulatory Care

A parallel and equally consequential trend is the migration of hospital-grade monitoring into the home and into lower-acuity care settings. Royal Philips and Masimo renewed and expanded their multi-year strategic partnership in September 2025, agreeing to integrate Masimo's SET pulse oximetry, Radius PPG wearable sensing, and other monitoring technologies more deeply into Philips' multi-parameter patient-monitoring platforms while jointly developing AI-based monitoring algorithms. In their respective announcements, both companies frame the collaboration around extending validated physiologic monitoring beyond the bedside, supporting greater patient mobility and continuity of monitoring as patients move between the hospital, transitional care, and home.

This home-monitoring push is not limited to established medical device incumbents. Specialist biosensor companies such as VitalConnect and BioIntelliSense have built businesses specifically around continuous, patch-based vital-sign monitoring for inpatient deterioration detection and post-discharge transitional care, while device makers like Biolinq are pursuing minimally invasive biosensor patches aimed at non-insulin type 2 diabetes populations who fall outside the traditional CGM prescribing base. The common thread across these companies is a bet that remote patient monitoring, once a niche reimbursement category, is becoming a standard extension of how health systems manage chronic disease and post-acute recovery, driven by workforce shortages, rising patient acuity, and payer interest in reducing avoidable hospital readmissions.

Conclusion: What This Means for Patients, Clinicians, and the Industry

The wearable medical devices market is no longer best described as a fitness-tracker industry with a few medical add-ons; it is becoming a genuine extension of the diagnostic and monitoring infrastructure of healthcare itself. The clearances and partnerships detailed above, extended-wear glucose sensors, FDA-cleared hypertension and sleep apnea detection, hospital-grade pulse oximetry shrunk into a watch, and monitoring platforms extending from the ICU into the living room, collectively point toward a healthcare model where continuous, passive data collection plays a larger role in catching chronic and cardiovascular disease earlier, against a backdrop of diabetes and cardiovascular disease burdens that the WHO and IDF both describe as still rising.

For companies operating in this space, the strategic lessons are converging: clinical credibility, built through rigorous FDA clearance, is becoming a genuine competitive differentiator rather than a regulatory afterthought, software and AI model quality now matter as much as sensor hardware; and distribution partnerships that combine a specialist's clinical validation with a consumer brand's reach, Dexcom and Oura, Philips and Masimo are emerging as a preferred route to scale. For patients and clinicians, the practical result is a growing set of tools capable of surfacing warning signs earlier than periodic clinical visits ever could, provided the industry continues to pair that reach with the regulatory rigor, transparency, and privacy safeguards that clinical-grade claims demand.